Ascentage Pharma AAPG
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 98th percentile, 5-year average -22.2x
Below its usual level · 33rd percentile, 5-year average 32.5x
#5093 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 14th percentile, 5-year average 29.6x
#4634 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 16.39 | – | 32.46 | 33% (cheaper than usual) | #5093 of 5330 (1 = cheapest) |
| PE | -6.21 | -7.42 | -22.24 | 98% (pricier than usual) | – |
| PS | 14.17 | 13.01 | 29.63 | 14% (cheaper than usual) | #4634 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AAPG.
Sign in to join the discussion.